Alogliptin: Safety, efficacy, and clinical implications

Journal of Pharmacy Practice

Volumn 28, Issue 1, 2015, Pages 99-106

  Marino, Adriane B ^a   Cole, Sabrina W ^a  

^a WINGATE UNIVERSITY   (United States)

Author keywords

alogliptin; dipeptidyl peptidase 4 (DPP 4) inhibitor; oral antidiabetic agent; type 2 diabetes

Indexed keywords

ALOGLIPTIN; GLUCAGON LIKE PEPTIDE 1; GLUCOSE; HEMOGLOBIN A1C; INSULIN; ANTIDIABETIC AGENT; DIPEPTIDYL PEPTIDASE IV INHIBITOR; GLUCOSE BLOOD LEVEL; GLYCOSYLATED HEMOGLOBIN; PIPERIDINE DERIVATIVE; URACIL;

ACUTE PANCREATITIS; ARTICLE; CARDIOVASCULAR DISEASE; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG SAFETY; DRUG TOLERABILITY; FOOD AND DRUG ADMINISTRATION; GERIATRICS; GLUCOSE HOMEOSTASIS; HUMAN; HYPOGLYCEMIA; INSULIN RELEASE; LACTATION; LIVER DISEASE; MEDICAL RESEARCH; MONOTHERAPY; NON INSULIN DEPENDENT DIABETES MELLITUS; PANCREAS ISLET BETA CELL; PREGNANCY; ANALOGS AND DERIVATIVES; BODY WEIGHT; DIABETES MELLITUS, TYPE 2; DRUG COMBINATION; DRUG EFFECTS; GLUCOSE BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL (TOPIC);

BLOOD GLUCOSE; BODY WEIGHT; DIABETES MELLITUS, TYPE 2; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; DRUG THERAPY, COMBINATION; GLUCAGON-LIKE PEPTIDE 1; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; PIPERIDINES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; URACIL;

EID: 84924856228     PISSN: 08971900     EISSN: 15311937     Source Type: Journal    
DOI: 10.1177/0897190014522063     Document Type: Article

References (18)

1. American Diabetes Association. National Diabetes Fact Sheet; 2011. http://www.diabetes.org/diabetes-basics/diabetes-statistics/. Accessed May 20, 2013.
2. Moss SE, Klein R, Klein BE, et al. The association of glycemia and cause specific mortality in a diabetic population. Arch Intern Med. 1994 ; 154 (21). 2473-2479
3. Patel A, MacMahon S, Chalmers J, et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med. 2008 ; 358 (24). 2560-2572
4. Ray KK, Seshasai SE, Wijesuriya S, et al. Effect of intensive control of glucose on cardiovascular outcomes and death in patients with diabetes mellitus: a meta-analysis of randomized controlled trials. Lancet. 2009 ; 373 (9677). 1765-1772
5. Ong KL, Cheung BM, Wong LY, et al. Prevalence, treatment, and control of diagnosed diabetes in the US national health and nutrition examination survey 1994-2004. Ann Epidemiol. 2008 ; 18 (3). 222-229
6. Deerfield, IL: Takeda Pharmaceuticals America, Inc ; 2013:
7. DeFronzo RA, Fleck PR, Wilson CA, et al. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin in patients with type 2 diabetes and inadequate glycemic control. Diabetes Care. 2008 ; 31 (12). 2315-2317
8. Rosenstock J, Inzucchi S, Seufert J, et al. Initial combination therapy with alogliptin and a pioglitazone in drugnaïve patients with type 2 diabetes. Diabetes Care. 2010 ; 33 (11). 2406-2408
9. Nauck MA, Ellis GC, Fleck PR, et al. Efficacy and safety of adding the dipeptidyl peptidase-4 inhibitor alogliptin to metformin therapy in patients with type 2 diabetes inadequately controlled with metformin monotherapy: a multicentre, randomised, double-blind, placebo-controlled study. Int J Clin Pract. 2009 ; 63 (1). 46-55
10. DeFronzo RA, Burant CF, Fleck P, et al. Efficacy and tolerability of the DPP-4 inhibitor alogliptin combined with pioglitazone, in metformin-treated patients with type 2 diabetes. J Clin Endocrinol Metab. 2012 ; 97 (5). 1615-1622
11. Pratley RE, Reusch JE, Fleck PR, et al. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin added to pioglitazone in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled study. Curr Med Res Opin. 2009 ; 25 (10). 2361-2371
12. Bosi E, Ellis GC, Wilson CA, et al. Alogliptin as a third oral antidiabetic drug in patients with type 2 diabetes and inadequate glycaemic control on metformin and pioglitazone: a 52-week, randomized, double-blind, active-controlled, parallel-group study. Diabetes Obes Metab. 2011 ; 13 (12). 1088-1096
13. Pratley R, Kipnes M, Fleck P, et al. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin in patients with type 2 diabetes inadequately controlled by glyburide monotherapy. Diabetes Obes Metab. 2009 ; 11 (2). 167-176
14. Rosenstock R, Rendell MS, Gross JL, et al. Alogliptin added to insulin therapy in patients with type 2 diabetes reduces HbA1c without causing weight gain or increased hypoglycemia. Diabetes Obes Metab. 2009 ; 11 (12). 1145-1152
15. Rosenstock J, Wilson C, Fleck P. Alogliptin versus glipizide monotherapy in elderly type 2 diabetes mellitus patients with mild hyperglycemia: a prospective, double-blind, randomized, 1-year study. Diabetes Obes Metab. 2013 ; 15 (10). 906-914
16. White W, Cannon C, Heller S, et al. Alogliptin after acute coronary syndrome in patients with type 2 diabetes. N Engl J Med. 2013 ; 369 (14). 1327-1335
17. Selvin E, Coresh J, Brancati FL. The burden and treatment of diabetes in elderly individuals in the US. Diabetes Care. 2006 ; 29 (11). 2415-2419
18. Pratley RE, McCall T, Fleck PR, et al. Alogliptin use in elderly people: a pooled analysis from phase 2 and 3 studies. J Am Geriatr Soc. 2009 ; 57 (11). 2011-2019